MD Anderson Cancer Center and SOPHiA GENETICS announced a strategic collaboration to accelerate AI-powered precision oncology, combining joint research, development programs, and a co-developed next-generation sequencing oncology test built on SOPHiA’s DDM platform.

The partnership aims to translate complex multimodal data into actionable clinical insights at scale, enabling rapid interpretation of RNA-sequencing data to guide cancer diagnosis and treatment.

MD Anderson leadership for the project includes Shashikant Kulkarni and J. Bryan, who will guide research efforts in molecular pathology and pathology/laboratory medicine.

The announcement is a public release from Mirage.News and reflects the perspectives of the collaborating organizations, not third-party endorsement.

SOPHiA DDM is presented as a unifying analytics layer, with emphasis on growing market interest in AI-enabled partnerships within SOPHiA’s ecosystem.

The press release contains standard forward-looking statements and notes that SOPHiA products are for Research Use Only unless specified otherwise.

It is emphasized that products are for research use unless explicitly designated for diagnostic use, aligning with SOPHiA’s broader initiatives and oncology genomics partnerships.

The document includes typical product-use and forward-looking disclosures common to corporate press releases.

BTIG recently raised SOPHiA GENETICS’ price target to $7 with a Buy rating, citing proximity to an inflection point and potential stock appreciation.

The article notes content was AI-generated and edited, and places the collaboration within SOPHiA’s ongoing market strategy.

Background: SOPHiA GENETICS is a cloud-native healthcare technology company behind the SOPHiA DDM Platform; MD Anderson is a leading Houston-based, NCI-designated comprehensive cancer center.

Additional context reiterates SOPHiA as a cloud-native health tech player and MD Anderson’s stature, with standard regulatory disclosures in the press release.